JP2014526498A5 - - Google Patents

Download PDF

Info

Publication number
JP2014526498A5
JP2014526498A5 JP2014530354A JP2014530354A JP2014526498A5 JP 2014526498 A5 JP2014526498 A5 JP 2014526498A5 JP 2014530354 A JP2014530354 A JP 2014530354A JP 2014530354 A JP2014530354 A JP 2014530354A JP 2014526498 A5 JP2014526498 A5 JP 2014526498A5
Authority
JP
Japan
Prior art keywords
crystalline form
dichlorophenyl
carboxy
benzoxazole meglumine
crystal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014530354A
Other languages
English (en)
Japanese (ja)
Other versions
JP5869677B2 (ja
JP2014526498A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2012/054748 external-priority patent/WO2013038351A1/en
Publication of JP2014526498A publication Critical patent/JP2014526498A/ja
Publication of JP2014526498A5 publication Critical patent/JP2014526498A5/ja
Application granted granted Critical
Publication of JP5869677B2 publication Critical patent/JP5869677B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014530354A 2011-09-16 2012-09-12 トランスサイレチン解離阻害剤の固体形態 Expired - Fee Related JP5869677B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161535551P 2011-09-16 2011-09-16
US61/535,551 2011-09-16
PCT/IB2012/054748 WO2013038351A1 (en) 2011-09-16 2012-09-12 Solid forms of a transthyretin dissociation inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016001888A Division JP2016128444A (ja) 2011-09-16 2016-01-07 トランスサイレチン解離阻害剤の固体形態

Publications (3)

Publication Number Publication Date
JP2014526498A JP2014526498A (ja) 2014-10-06
JP2014526498A5 true JP2014526498A5 (cg-RX-API-DMAC10.html) 2015-07-30
JP5869677B2 JP5869677B2 (ja) 2016-02-24

Family

ID=47116132

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014530354A Expired - Fee Related JP5869677B2 (ja) 2011-09-16 2012-09-12 トランスサイレチン解離阻害剤の固体形態
JP2016001888A Pending JP2016128444A (ja) 2011-09-16 2016-01-07 トランスサイレチン解離阻害剤の固体形態

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016001888A Pending JP2016128444A (ja) 2011-09-16 2016-01-07 トランスサイレチン解離阻害剤の固体形態

Country Status (16)

Country Link
US (2) US9249112B2 (cg-RX-API-DMAC10.html)
EP (1) EP2755961A1 (cg-RX-API-DMAC10.html)
JP (2) JP5869677B2 (cg-RX-API-DMAC10.html)
KR (1) KR20140054231A (cg-RX-API-DMAC10.html)
CN (1) CN103781770B (cg-RX-API-DMAC10.html)
AR (1) AR088755A1 (cg-RX-API-DMAC10.html)
AU (1) AU2012310157B2 (cg-RX-API-DMAC10.html)
BR (1) BR112014005810A2 (cg-RX-API-DMAC10.html)
CA (1) CA2847293C (cg-RX-API-DMAC10.html)
IL (1) IL231472A0 (cg-RX-API-DMAC10.html)
MX (1) MX2014003043A (cg-RX-API-DMAC10.html)
RU (1) RU2586330C2 (cg-RX-API-DMAC10.html)
SG (1) SG2014013270A (cg-RX-API-DMAC10.html)
TW (2) TWI476185B (cg-RX-API-DMAC10.html)
WO (1) WO2013038351A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201401202B (cg-RX-API-DMAC10.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06105459B2 (ja) * 1988-08-11 1994-12-21 日本電気株式会社 ベクトル処理装置
WO2013038351A1 (en) * 2011-09-16 2013-03-21 Pfizer Inc. Solid forms of a transthyretin dissociation inhibitor
EP2764866A1 (en) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
HUE056583T2 (hu) * 2014-09-08 2022-02-28 Pfizer 6-Karboxi-2-(3,5-diklórfenil)-benzoxazol kristályos szilárd formái
CN107344927A (zh) * 2016-05-05 2017-11-14 苏州晶云药物科技有限公司 Tafamidis葡甲胺盐的晶型E及其制备方法和用途
GB2571950A (en) * 2018-03-13 2019-09-18 Azad Pharma Ag New polymorph and new path to synthesize tafamidis
WO2020128816A2 (en) 2018-12-20 2020-06-25 Pfizer Inc. Pharmaceutical compositions and methods comprising a combination of a benzoxazole transthyretin stabilizer and an additional therapeutic agent
US12116352B2 (en) 2019-04-11 2024-10-15 Inke, S.A. Process for preparing 1-deoxy-1-methylamino-d-glucitol 2-(3,5-dichlorophenyl)-6-benzoxazolecarboxylate
HRP20250159T1 (hr) 2019-05-16 2025-03-28 Assia Chemical Industries Ltd. Kruti oblici tafamidisa i njegovih soli
MX2021014682A (es) * 2019-05-31 2022-04-06 Plex Pharmaceuticals Inc Agentes farmacológicos para tratar enfermedades de agregación de proteínas de los ojos.
WO2021019448A1 (en) * 2019-08-01 2021-02-04 Honour (R&D) Process for the preparation of transthyretin dissociation inhibitor
EP4059926A4 (en) * 2019-11-15 2022-12-14 Crystal Pharmaceutical (Suzhou) Co., Ltd. CRYSTALLINE FORM OF TAFAMIDIS AND PROCESS FOR PRODUCTION AND USE THEREOF
HRP20251570T1 (hr) 2019-12-20 2026-01-30 Pfizer Ireland Pharmaceuticals Unlimited Company Djelotvoran postupak dobivanja derivata 6-karboksibenzoksazola
WO2021232619A1 (zh) * 2020-05-19 2021-11-25 苏州科睿思制药有限公司 一种他发米帝司游离酸的晶型及其制备方法和用途
WO2022009221A1 (en) * 2020-07-04 2022-01-13 Nuray Chemicals Private Limited Solid state forms of 6-carboxy-2-(3, 5-dichlorophenyl)-benzoxazole of formula-i and pharmaceutically acceptable salts thereof
FR3114230B1 (fr) 2020-09-23 2022-12-23 Pierre Berger Dispositif de connexion entre une toile et un rail
WO2022084790A1 (en) * 2020-10-19 2022-04-28 Glenmark Life Sciences Limited Process for preparation of tafamidis and salts thereof
WO2022112919A1 (en) 2020-11-25 2022-06-02 Pfizer Inc. (aza)benzothiazolyl substituted pyrazole compounds
EP4083027A1 (en) 2021-04-26 2022-11-02 Química Sintética, S.A. A solid state form of tafamidis and a process for its preparation
WO2023020762A1 (en) 2021-08-16 2023-02-23 Synthon B.V. Crystalline forms of tafamidis nicotinamide adduct
WO2023091534A1 (en) 2021-11-17 2023-05-25 Teva Pharmaceuticals International Gmbh Solid state form of tafamidis

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602336C (de) 1933-03-09 1934-09-06 I G Farbenindustrie Akt Ges Verfahren zur Herstellung von Kuepenfarbstoffen der Anthrachinonreihe
US3551433A (en) 1967-06-21 1970-12-29 Us Army Preparation of 4-phenyl-4-acyloxypiperidine
US3551443A (en) 1968-10-30 1970-12-29 Ciba Ltd 2-phenylbenzoxazole derivatives
USRE29608E (en) 1972-05-18 1978-04-11 Lilly Industries Limited Benzoxazole derivatives
DE2314238A1 (de) 1973-03-22 1974-09-26 Henkel & Cie Gmbh Neue 2-(tetrazol-5'-yl)-benzoxazole, deren herstellung sowie verwendung als entzuendungshemmer in kosmetischen praeparationen
US4025637A (en) 1973-10-23 1977-05-24 Lilly Industries, Ltd. 2,5 OR 2,6 Disubstituted benzoxazoles
US4025636A (en) 1973-10-23 1977-05-24 Lilly Industries, Ltd. 2-(Optionally substituted)phenyl-5 or 6-substituted benzoxazoles
GB1488003A (en) * 1973-10-23 1977-10-05 Lilly Industries Ltd 1,2-benzisoxazole derivatives processes for their preparation and their use as pharmaceuticals
DE2619547A1 (de) 1976-05-04 1977-11-24 Dynamit Nobel Ag Verfahren zur herstellung von 2-aryl- benzoxazolen und 2-aryl-benzthiazolen
US4416892A (en) 1981-04-23 1983-11-22 Lilly Industries Limited Method of treating hypersensitivity disease with benzoxazole derivatives
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
DE4011106A1 (de) 1990-04-06 1991-10-10 Bayer Ag Neue heterocyclisch substituierte dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
US5254692A (en) 1990-04-06 1993-10-19 Bayer Aktiengesellschaft 2,6-dialkyl-4-(benzothiazol- or benzoxazol-7-yl)-1,4-dihydropyridines
US5037842A (en) 1990-06-05 1991-08-06 Pfizer Inc. Oxa- and thiazolidinedione hypoglycemic and hypocholesterolemic agents
CA2051518A1 (en) 1990-10-01 1992-04-02 Robert J. Perry Synthesis of heterocyclic compounds
CH681806A5 (cg-RX-API-DMAC10.html) 1991-03-19 1993-05-28 Ciba Geigy Ag
US5354759A (en) 1991-09-12 1994-10-11 Fujisawa Pharmaceutical Co., Ltd. Angiotenin II antagonizing heterocyclic compounds
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
GB9218334D0 (en) 1992-08-28 1992-10-14 Ici Plc Heterocyclic compounds
DE4304650A1 (de) 1993-02-16 1994-08-18 Thomae Gmbh Dr K Kondensierte 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US5441946A (en) 1994-04-14 1995-08-15 Rhone-Poulenc-Rorer Pharmaceuticals, Inc. Phosphonate derivatives of lipophilic amines
US5552426A (en) 1994-04-29 1996-09-03 Eli Lilly And Company Methods for treating a physiological disorder associated with β-amyloid peptide
US5837390A (en) 1995-05-10 1998-11-17 Sony Corporation Metal complex, method for producing the same and optical device
WO1998027972A2 (en) 1996-12-23 1998-07-02 Texas A & M University Anti-amyloidogenic agents
FR2767527B1 (fr) 1997-08-25 1999-11-12 Pf Medicament Derives de piperazines indoliques, utiles comme medicaments et procede de preparation
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
AU2494799A (en) 1998-02-04 1999-08-23 Board Of Regents, The University Of Texas System Inhibition of human telomerase by a g-quadruplex-interaction compound
US6107491A (en) 1998-07-20 2000-08-22 Ciba Specialty Chemicals Corporation Polymerizable diketopyrrolopyrroles
GB9816654D0 (en) 1998-07-30 1998-09-30 Zeneca Ltd Chemical compounds
WO2000078733A1 (de) 1999-06-18 2000-12-28 Bayer Aktiengesellschaft Phenoxyfluorpyrimidine
AU6903200A (en) 1999-08-16 2001-03-13 Merck & Co., Inc. Heterocycle amides as cell adhesion inhibitors
GB9919673D0 (en) 1999-08-20 1999-10-20 Cancer Res Campaign Tech 2-Arlybenzazole compounds
JP2001226358A (ja) 1999-10-12 2001-08-21 Japan Tobacco Inc Ｌｐｌ活性増強剤
JP3938689B2 (ja) 2000-03-16 2007-06-27 エフ．ホフマン−ラ ロシュ アーゲー Ｉｐアンタゴニストとしてのカルボン酸誘導体
GB0007934D0 (en) 2000-03-31 2000-05-17 Darwin Discovery Ltd Chemical compounds
RU2324686C2 (ru) 2000-08-24 2008-05-20 Юнивесити Оф Питсбэг ПРОИЗВОДНЫЕ ТИОФЛАВИНА, СВЯЗЫВАЮЩИЕ АМИЛОИД, СПОСОБ ОБНАРУЖЕНИЯ in vivo ОТЛОЖЕНИЙ АМИЛОИДА И СПОСОБ РАСПОЗНАВАНИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА
CA2427750C (en) 2000-11-04 2011-01-04 Aventis Pharma Limited Substituted alkanoic acids
JP2004515496A (ja) 2000-12-07 2004-05-27 アストラゼネカ・アクチエボラーグ ベンズイミダゾール治療剤
WO2002051821A1 (en) 2000-12-22 2002-07-04 Astrazeneca Ab Therapeutic compounds
GB0118357D0 (en) 2001-07-27 2001-09-19 Syngenta Ltd Chemical compounds
AU2002334355A1 (en) 2001-09-06 2003-03-18 Prochon Biotech Ltd. Protein tyrosine kinase inhibitors
US6602619B2 (en) 2001-10-19 2003-08-05 Lightronik Technology Inc. Organic EL device
ES2309213T3 (es) 2001-11-16 2008-12-16 Nippon Chemiphar Co., Ltd. Inhibidor de xantina-oxidasa.
AU2002353739A1 (en) 2001-11-28 2003-06-10 Astrazeneca Ab Therapeutic compounds
UA83620C2 (ru) 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
WO2003053359A2 (en) 2001-12-19 2003-07-03 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
CN1596240A (zh) 2001-12-19 2005-03-16 阿特罗吉尼克斯公司 查耳酮衍生物及其治疗疾病的用途
GB0205256D0 (en) 2002-03-06 2002-04-17 Oxford Glycosciences Uk Ltd Novel compounds
MXPA04009040A (es) 2002-03-20 2005-01-25 Metabolex Inc Acidos fenilaceticos sustituidos.
UA79755C2 (en) 2002-04-16 2007-07-25 Bayer Pharmaceuticals Corp Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
GB0226822D0 (en) 2002-11-16 2002-12-24 Oxford Glycosciences Uk Ltd Novel compounds
DK1587821T6 (da) 2002-12-19 2025-05-26 Scripps Research Inst Sammensætninger og fremgangsmåder til stabilisering af trans-thyretin og inhibering af transthyretin-fejlfoldning
JP2006517925A (ja) 2003-01-14 2006-08-03 メルク　エンド　カムパニー　インコーポレーテッド Ａβ４２低下薬としてのジェミナル二置換ＮＳＡＩＤ誘導体
CA2438032C (en) 2003-03-14 2013-05-07 University Of Pittsburgh Benzothiazole derivative compounds, compositions and uses
MY142651A (en) 2003-03-18 2010-12-15 Merck Sharp & Dohme Biaryl substituted triazoles as sodium channel blockers
WO2004084824A2 (en) 2003-03-24 2004-10-07 Merck & Co., Inc. Biaryl substituted 6-membered heterocyles as sodium channel blockers
CA2520804A1 (en) 2003-04-03 2004-10-28 Merck & Co., Inc. Biaryl substituted pyrazoles as sodium channel blockers
CA2522476A1 (en) 2003-04-18 2004-11-04 Merck & Co., Inc. Biaryl substituted thiazoles, oxazoles and imidazoles as sodium channel blockers
WO2004098494A2 (en) 2003-04-30 2004-11-18 Cytokinetics, Inc. Compounds, compositions, and methods
WO2005112913A1 (en) 2004-05-20 2005-12-01 The Scripps Research Institute Transthyretin stabilization
WO2011116123A1 (en) 2010-03-19 2011-09-22 Irm Llc Tafamidis for the treatment of ophthalmic diseases
WO2013038351A1 (en) * 2011-09-16 2013-03-21 Pfizer Inc. Solid forms of a transthyretin dissociation inhibitor
WO2013166041A1 (en) 2012-05-01 2013-11-07 The Trustees Of Columbia University In The City Of New York Transthyretin ligands capable of inhibiting retinol-dependent rbp4-ttr interaction for treatment of age-related macular
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy

Similar Documents

Publication Publication Date Title
JP2016065042A5 (cg-RX-API-DMAC10.html)
JP2015010091A5 (cg-RX-API-DMAC10.html)
HRP20211834T1 (hr) Kristalni čvrsti oblici 6-karboksi-2-(3,5-diklorfenil)benzoksazola
RU2014109676A (ru) Твердые формы ингибитора диссоциации транстиретина
HRP20210507T1 (hr) Supstituirani 5-fluoro-1h-pirazolopiridini u kristalnom obliku
JP2011168587A5 (cg-RX-API-DMAC10.html)
JP2015525757A5 (cg-RX-API-DMAC10.html)
JP2012531408A5 (cg-RX-API-DMAC10.html)
JP2018035160A5 (cg-RX-API-DMAC10.html)
JP2013514381A5 (cg-RX-API-DMAC10.html)
HRP20161742T1 (hr) Soli i polimorfi od 8-fluoro-2-{4-[(metilamino)metil]fenil}-1,3,4,5-tetrahidro-6h-azepino[5,4,3-cd]indol-6-ona
JP2015044837A5 (cg-RX-API-DMAC10.html)
JP2013521273A5 (cg-RX-API-DMAC10.html)
JP2013534511A5 (cg-RX-API-DMAC10.html)
RU2017141763A (ru) Кристалл (6S,9aS)-N-бензил-8-({ 6-[3-(4-этилпиперазин-1-ил)азетидин-1-ил]пиридин-2-ил} метил)-6-(2-фтор-4-гидроксибензил)-4,7-диоксо-2-(проп-2-ен-1-ил)гексагидро-2H-пиразино[2,1-c][1,2,4]триазин-1(6H)-карбоксамида
JP2009529541A5 (cg-RX-API-DMAC10.html)
CN103717571B8 (zh) 9‑氨基甲基取代的四环素类化合物
JP2012176975A5 (cg-RX-API-DMAC10.html)
HRP20170540T1 (hr) Spojevi dimetilbenzojeve kiseline, korisni u liječenju upalnih stanja
JP2012036197A5 (cg-RX-API-DMAC10.html)
JP2014530818A5 (cg-RX-API-DMAC10.html)
JP2011242375A5 (cg-RX-API-DMAC10.html)
JP2015522037A5 (cg-RX-API-DMAC10.html)
JP2012516348A5 (cg-RX-API-DMAC10.html)
JP2016510767A5 (cg-RX-API-DMAC10.html)